Kiora Pharmaceuticals Azioni (NASDAQ: KPRX)

Ultime notizie per Kiora Pharmaceuticals (NASDAQ:KPRX) Azioni

Kiora Pharmaceuticals

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals Inc

WIIM

SMCI

Super Micro Computer shares are trading lower after JP Morgan downgraded the stock from Neutral to Underweight and cut its price target on the stock from $50 to $23.

Pinnacle West Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) reported quarterly earnings of $3.37 per share which missed the analyst consensus estimate of $3.48 by 3.16 percent. This is a 3.71 percent decrease over earnings of $3.50 per share from the same period last year. The company reported quarterly sales of $1.77 billion which missed the analyst consensus estimate of $1.87 billion by 5.65 percent. This is a 7.94 percent increase over sales of $1.64 billion the same period last year.

Earnings

Earnings Misses

News

Pinnacle West Capital Q3 2024 GAAP EPS $3.37 Misses $3.48 Estimate, Sales $1.77B Miss $1.87B Estimate

Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 binding protein (IL-18BP)
IL-18 has significant importance for cancer immune-oncology and combination with IL-12 on Sonnet's FHAB platform which Sonnet believes could&nbsp;present an important oncology possibility
The lock-and-load flexibility of the FHAB platform offers the bifunctional payload capability of adding another synergistic biologics target to IL-18 generating multiple novel cancer drugs
PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,134,635 entitled "Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same," covering two of its novel drug candidates, SON-1411 (IL-18BPR-FHAB-IL12) and SON-1400 (IL-18BPR-FHAB), each containing a modified version of recombinant human interleukin-18 (IL-18BPR = Binding Protein Resistant). The patent carries a term effective until June 2044.

Biotech

General

SONN

Sonnet BioTherapeutics Announces Issuance Of U.S. Patent Covering A Variant IL-18 Incorporated Into Two Novel Immunotherapeutic Drug Candidates; Both Novel Bifunctional And Monofunctional Fusion Proteins Exhibit Wild-Type Binding To The IL-18 Receptor, Coupled With Undetectable Binding To The Inhibitory IL-18 Binding Protein

ANIX

Anixa Biosciences Sets November 8 For Public Release Of Phase 1 Breast Cancer Vaccine Data At SITC Annual Meeting

TD Cowen analyst Nick Yako maintains Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) with a Hold and raises the price target from $130 to $150.

Price Target

Analyst Ratings

QLYS

TD Cowen Maintains Hold on Qualys, Raises Price Target to $150

Management

FTHM

Fathom Holdings Announced It Has Promoted Joanne Zach To CFO

<ul>
<li>$800 Million AAA-Rated Personal Loan and $200 Million AA-Rated Auto Loan Asset Backed Securitizations, with $5.5 Billion raised across all ABS transactions year-to-date</li>
<li>Pagaya remains the #1 personal loan ABS issuer in the U.S.</li>
</ul>
Pagaya Technologies LTD. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) ("Pagaya" or "the Company"), a global technology company delivering AI-driven product solutions for the financial ecosystem, today announced the closing of PAID 2024-10 and RPM 2024-3, totaling $1 billion in size across both deals. This represents the Company's fourth AAA-rated personal loan ABS transaction and its first AA-rated auto ABS transaction.
A total of 28 unique investors participated across these two transactions, the majority of which were repeat investors. The deal was substantially oversubscribed, reflecting continued strong investor demand for Pagaya's robust, AI-enabled consumer credit assets.
Pagaya continues to meet the needs of prominent financial institutions and deliver efficient, fit-for-market structures across the financial ecosystem. Qualified institutional buyers purchased notes backed by personal and auto loans that will be originated by Pagaya's lending partners on Pagaya's AI-powered network.

Pagaya Raises $1B Across Two New Personal Loan And Auto ABS Deals, Signaling Strong Capital Markets Demand; A Total Of 28 Investors Participated Across These Two Transactions, The Majority Of Which Were Repeat Investors

Cummins shares are trading higher after Baird raised its price target on the stock from $330 to $372.

MFA Finl Q3 2024 Distributable EPS $0.37, NII $50.625M

GlobalFoundries shares are trading higher. Baird maintained an Outperform rating on the stock.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/580f253b846faa000139ba71/robert-moskow">TD Cowen analyst Robert Moskow</a> upgraded the rating for The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from Sell to Hold and raises the price target from $155 to $170. Clorox shares closed at $162.42 on Tuesday. <a href="https://www.benzinga.com/quote/CLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Trevor Young upgraded Revolve Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) from Underweight to Equal-Weight and raised the price target from $17 to $25. Revolve shares closed at $26.02 on Tuesday. <a href="https://www.benzinga.com/quote/RVLV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/616e99feb650db000151570b/rick-bienkowski">Leerink Partners analyst Rick Bienkowski</a> upgraded the rating for Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) from Market Perform to Outperform and increased the price target from $27 to $39. Beam Therapeutics shares closed at $23.93 on Tuesday. <a href="https://www.benzinga.com/quote/BEAM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst David Begleiter upgraded Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Hold to Buy and lowered the price target from $135 to $110. Celanese shares closed at $91.00 on Tuesday. <a href="https://www.benzinga.com/quote/CE/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>

Considering buying CLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="547" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-1024x547.png" alt="" class="wp-image-632747" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-1024x547.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-768x410.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49.png 1230w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

Upgrades

Pre-Market Outlook

Markets

Trading Ideas

BEAM

RVLV

This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday

TSLA

Tesla shares are trading higher following Donald Trump's successful presidential election campaign.

Guidance

CVS Executive Says Company Is Not Providing A Formal Outlook For 2024 At This Stage

Chubb shares are trading higher. Wells Fargo raised its price target on the stock from $106 to $108.

Health Care

STXS

Stereotaxis Announces University Of Kansas Medical Center Physicians Have Treated The First Patients Using The Company's Genesis Robotic Magnetic Navigation System

Aflac shares are trading higher. Wells Fargo raised its price target on the stock from $106 to $107.

TD Cowen analyst Oliver Chen downgrades Grocery Outlet Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>) from Buy to Hold and lowers the price target from $25 to $16.

Downgrades

TD Cowen Downgrades Grocery Outlet Holding to Hold, Lowers Price Target to $16

Contracts

YYGH

YY Group Holding's Hong Ye Group Announces SGD$4.7M In Contracts

TD Cowen analyst Vivien Azer downgrades Brown-Forman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) from Buy to Hold and lowers the price target from $50 to $48.

BF/B

TD Cowen Downgrades Brown-Forman to Hold, Lowers Price Target to $48

CHTR

Charter Communications shares are trading higher after Benchmark maintained a Buy rating on the stock and raised its price target from $440 to $450.

Maxim Group analyst Michael Okunewitch maintained a Buy rating on Kiora Pharmaceuticals (KPRX – Research Report) yesterday and set a price target o...

Buy Rating on Kiora Pharmaceuticals Amid Strong Financials and Promising Clinical Trials

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Kiora Pharmaceuticals (KPRX – Research Report), retaining the price target of $2.00. ...

Buy Rating for Kiora Pharmaceuticals Bolstered by Strong Financials and Promising Clinical Trial Data

The latest announcement is out from Kiora Pharmaceuticals (KPRX). The Company has made headlines by announcing Ms. Walters-Hoffert's appointment to...

Kiora Pharmaceuticals Announces Board Appointment, Regains Nasdaq Compliance

Kiora Pharmaceuticals GAAP EPS of -$0.53 beats by $0.33

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Kiora Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/kprx-stock-quote/">KPRX</a>) just reported results for the second quarter of 2024.<ul><li>Kiora Pharmaceuticals reported earnings per share of -53 cents. This was above the analyst estimate for EPS of -81 cents.</li><li>The company reported revenue of $20,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/kprx-stock-earnings-kiora-pharmaceuticals-for-q2-of-2024/">KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q2 2024

Analyst Michael Okunewitch of Maxim Group maintained a Buy rating on Kiora Pharmaceuticals (KPRX – Research Report), with a price target of $27.00....

Buy Rating on Kiora Pharmaceuticals: Strong Financials and Promising KIO-301 Progress

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Kiora Pharmaceuticals (KPRX – Research Report), retaining the price target of $10.00....

Buy Rating on Kiora Pharmaceuticals Amid Promising Clinical Trials and Strong Financials

Kiora Pharmaceuticals ( ($KPRX) ) has issued an update. Kiora Pharmaceuticals has received regulatory approval to begin a Phase 2 clinical trial of...

Comments

Kiora Pharmaceuticals

Notizie

Ultime notizie per Kiora Pharmaceuticals (NASDAQ:KPRX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO